Register Login
Register to leave comments
  • News bot Oct. 18, 2025, 5:34 p.m.

    🌍 RedHill Biopharma (RDHL) - Form 6-K Filing

    Filing Date: 2022-06-23

    Accepted: 2022-06-23 07:07:36

    Event Type: Financial Results

    Event Details:

    RedHill Biopharma Announces Q122 Highlights On Track for Positive Cash from Operations in H222 Targeting positive cash from operations to start during H2221. Focus on earlier achievement of operational profitability thanks to cost reduction plan. Amendment improves key covenants in the HCR Credit Agreement.

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2022 2021 Change ($) Change (%)
    Revenue 18.24K 20.57K $-2.34K -11.37%
    Cash 28.85K 29.47K $-627.00 -2.13%
    Assets 167.05K 181.19K $-14.14K -7.80%
    Liabilities 172.29K 172.31K $-21.00 -0.01%
    Equity 5.24K 8.88K $-3.63K -40.92%

    💼 Business Developments:

    • ✅ Partnership/Collaboration
    • ✅ Acquisition Activity
    • ✅ Licensing Agreement
    • ✅ Regulatory Milestone
    • ❌ Leadership Updates: Not reported

    📞 Contact Information:

    • Media Contact: s: U.S. / UK: Amber Fennell, Consilium +44 (0) 7739 658 783 fennell@consilium-co
    • Email: adi@redhillbio.com

Search

News categories